All In Biotech

Drug Trial Radar · NCT05117554

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Nov 9, 2021

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Nov 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • casdatifanDrug

    Capsule

  • PlaceboDrug

    Capsule

  • MidazolamDrug

    Syrup solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 21.5 Weeks
  2. Number of Participants With Abnormal Changes From Baseline in Laboratory Parameter ValuesTime frame: Baseline; Up to 21.5 Weeks
  3. Number of Participants With Abnormal Changes from Baseline in Vital Sign ValuesTime frame: Baseline; Up to 21.5 Weeks
  4. Maximum Observed Plasma Concentration (Cmax) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  5. Area Under the Plasma Concentration Time Curve From Hour 0 to the Last Sample With Measurable Plasma Concentrations (AUClast) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  6. Time of Occurrence of Cmax (tmax) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  7. Apparent Terminal Elimination Rate Constant (λz) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  8. Terminal Half-Life (t1/2) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  9. Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUCinf) of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  10. Apparent Volume of Distribution of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks
  11. Apparent Total Body Clearance of casdatifanTime frame: multiple timepoints up to approximately 21.5 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.